What is the one step that belongs in every day?
Sun protection. I read the American Academy of Dermatology self-care page, and it says skin that has lost its color can burn readily. It names shade, clothing and labeled sunscreen as the broad options. That is the base the rest of a routine sits on. Evidence Evidence
- SPF rates sunburn protection, and sunburn is mostly caused by UVB.
- Broad spectrum means UVA cover too, and not every product carries it.
- No sunscreen is waterproof, whatever the front of the bottle suggests.
- Every sunscreen must carry directions for reapplication on the label.
Why this matters
- Sources cited, not yet graded
What a basic routine even looks like on skin without pigment is a question readers keep asking, and sun cover is where I would start. I then went through the FDA list of the spots people forget. Ears, nose, lips and the back of the neck are on that list. So are the hands, the tops of the feet, the hairline, and scalp where hair has thinned. Those are places a patch often sits.
Considerations
- Depends on you
For you, this is a habit rather than a calculation. Read the label and follow its own reapplication directions. Which product, how much, and how often are answers your own skin and your own day decide, with your dermatologist.
Questions for your dermatologist
Does the sunscreen I already use, ___, suit my patches and my face?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which parts of my body do you want covered first if I am short on time?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Do I need to protect my skin from ordinary bumps and rubbing?
Injury and friction are not the same question. The consensus guidance I read defines the Koebner phenomenon as patches growing where skin was not affected before and was then injured. The AAD names cuts, scrapes and burns among those injuries. Evidence Evidence
Why this matters
- Sources cited, not yet graded
I checked the other half in the same consensus, and it is direct. It says scientific evidence is lacking for blaming vitiligo on daily friction. It names washing, dressing, personal care, sports, work activity and pressure from clothing.
Considerations
- Depends on you
So what I would do is ordinary care. Treat a cut or a burn promptly. Keep a strap or a waistband from digging in when that is easy to do. I would not rebuild a day around rubbing, because the evidence for that is absent.
Questions for your dermatologist
I get a sore spot from ___ at work. Is that worth changing for my vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If I do cut or scrape my skin, what would you want me to watch for?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How should I be washing and moisturizing?
Gently. I read the British Association of Dermatologists leaflet on skin camouflage, and it says hard scrubbing can irritate skin. For taking cover off, it describes soap and water, a soap substitute, or an oil-based cleanser. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The leaflet adds a reason to do it daily that has nothing to do with cleanliness, and it is the line I would keep. A removal routine gives you a moment to look at the skin and notice change.
Considerations
- Depends on you
Scrubs and lightening products are the ones to raise before you buy. Skin lightening for vitiligo is a prescription matter. I read the archived US label for Benoquin (monobenzone) cream. It covers final depigmentation in extensive vitiligo, and says the skin stays sensitive for the rest of your life afterwards. An FDA record I checked says the branded product was no longer manufactured or distributed.
Questions for your dermatologist
Is there a cleanser or moisturizer you would recommend or avoid for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.I have been offered ___ to even out my skin tone. What do you make of it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Where does my prescribed cream fit around all this?
Where your prescriber puts it. The British guideline I read names potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. It names narrowband UVB as the first light option. Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
I checked the labels themselves, and they talk about ultraviolet light. The US label for Elidel (pimecrolimus) cream tells patients to avoid ultraviolet treatment and to minimize natural and artificial sunlight. The label for Protopic (tacrolimus) ointment carries ultraviolet instructions of its own. The label for Opzelura (ruxolitinib) cream carries skin-cancer and ultraviolet precautions, and points patients to the Medication Guide and their provider.
Considerations
- Depends on you
Apply what you were prescribed the way you were told to. I looked for the order of cream, moisturizer and sunscreen in these documents, and none of them sets one. Nor do they say what may sit on your skin on a light treatment day. Both are worth asking outright.
Questions for your dermatologist
In what order do you want me to put on ___ and my sunscreen?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Should my skin be bare of everything on the days I have light treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Do cover-up, self-tanner and hair dye belong in a skin care routine?
The first two sit right beside it, because they go on and come off daily. The same AAD page says self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Cover-up has a route through the clinic too. I read recommendation 28 of the British guideline, which offers a skin camouflage visit to anyone who wants one. That is a conversation to have rather than a product to hunt for alone.
Considerations
- Depends on you
Hair dye and other chemical products are thinner ground. NIAMS says an event such as sunburn, emotional distress or chemical exposure can sometimes trigger vitiligo or make it worse. I looked for a product or an ingredient named there, and found none, and no figure either. So the honest move is to name what you use and let your dermatologist weigh it.
Questions for your dermatologist
I dye my hair with ___. Is that worth a second look given my vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can you refer me to a skin camouflage service, and what does that visit cover?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that vitiligo is an autoimmune disease in which the immune system attacks melanocytes. Researchers believe family history and genes may play a role. An event such as sunburn, emotional distress, or chemical exposure can sometimes trigger vitiligo or make it worse. These are contributing factors, not a single determined cause repeated in every case.
What it does not support
It does not state that there is no single known cause. It does not rule out a specific trigger for one individual. It does not let a reader diagnose their own cause from a remembered event or timeline.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that the FDA regulates sunscreens as non-prescription drugs against safety and effectiveness standards. Every sunscreen is tested by comparing the amount of ultraviolet needed to cause sunburn with the product against the amount needed without it. An SPF value therefore rates sunburn protection, and because sunburn is mostly caused by UVB, SPF is primarily a UVB number. Broad spectrum products also protect against UVA, and not every product is broad spectrum. A product that is not broad spectrum, or that is under SPF 15, must carry a Drug Facts warning that it has only been shown to help prevent sunburn. It supports that SPF is not related to time in the sun, but to the amount of light. It supports that the amount changes with the time of day and with latitude, so someone nearer the equator gets more of it. It lists the permitted active ingredients, mineral and organic together, including titanium dioxide and zinc oxide, and records that bemotrizinol was added in June 2026. It supports that there is evidence at least some sunscreen active ingredients are absorbed through the skin, and that the FDA has requested data from industry to confirm their safety. It supports that no sunscreen is waterproof. A product labelled water resistant must be tested, and must state on its label how long it remains effective while swimming or sweating. Every sunscreen must carry directions for reapplication. It lists the frequently forgotten spots. They are the ears, nose, lips, back of the neck, hands, tops of the feet, along the hairline, and scalp exposed by thinning hair. It points to a lip balm carrying an SPF for the lips.
What it does not support
It is consumer guidance from a regulator, not a trial and not a comparison of products. It measures nothing about skin that has lost its pigment, and never mentions vitiligo. It ranks no brand and no ingredient. Its own recommendations carry numbers: an SPF floor, a reapplication interval, a midday window and an amount to apply. Every one of them is reported here as the FDA saying it, and never issued by this site as an instruction. It does not establish that any listed active ingredient is unsafe; it establishes that the FDA has asked for data. It cannot say what any product will do for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
Protopic (tacrolimus) ointment: US prescribing information and Medication Guide (opens in a new tab)
DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product. Its mechanism-of-action section supports that tacrolimus binds FKBP-12 to block calcineurin phosphatase, preventing the T-cell activation that its boxed warning and local-effect data describe. Its local-adverse-reaction data supports burning in roughly 46-58% and itching in roughly 41-46% of studied patients, most often in the first few days and easing as treatment continues. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms do not improve within six weeks.
What it does not support
It does not approve tacrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window are stated for its approved atopic-dermatitis indication, not as a vitiligo-specific schedule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight. This label itself is a generic pimecrolimus cream filing (packager Oceanside Pharmaceuticals, a division of Bausch Health US, LLC), not the original brand Elidel label, so it also supports that a generic pimecrolimus cream is currently marketed. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms persist beyond six weeks; its boxed warning separately supports that continuous long-term use should be avoided. Its adult 1-year active-comparator adverse-reaction table (328 pimecrolimus-treated subjects) supports application-site burning in about 25.9%, headache in about 25.4%, nasopharyngitis in about 7.6%, and influenza in about 9.8% of that adult trial population.
What it does not support
It does not approve pimecrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window, and its adult adverse-reaction percentages, are stated for its approved atopic-dermatitis indication and trial population, not as a vitiligo-specific schedule or vitiligo-trial safety rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It also supports the labeled dosing instruction: "Apply a thin layer of OPZELURA topically twice daily to affected areas of up to 10% body surface area." It further supports the labeled re-evaluation point: "If the patient does not find the repigmentation meaningful by 24 weeks, the patient should be re-evaluated by the healthcare provider." It also supports the vitiligo-trial adverse-reaction rates at 1% incidence or greater: application-site acne 6%, application-site itching 5%, a common-cold-type illness (nasopharyngitis) 4%, headache 4%, urinary tract infection 2%, application-site redness (erythema) 2%, and fever (pyrexia) 1%. It does not guarantee benefit, establish suitability beyond the labeled population, authorize adding phototherapy, or state which reaction should prompt a call to the prescriber beyond directing patients to the Medication Guide and their healthcare provider.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The product company authored the prescribing information hosted by FDA. It is authoritative for the historical label but not independent clinical evidence.
What this source supports
Supports the historical US indication for final depigmentation in extensive disseminated idiopathic vitiligo, the purpose and mechanism limits, permanence and distant-depigmentation warnings, listed reactions, contraindication boundary, and long-term unknowns. Re-read in full on 2026-08-21 for what it states about sun, which is in three places. Under Precautions, General, it states that following therapy with the cream the skin will be sensitive for the rest of the patient’s life, and that the person must use sunscreens during exposure to the sun. Under Clinical Pharmacology it states that exposure to sunlight reduces the depigmenting effect of the drug. The same section states that the histology of the skin after depigmentation with topical monobenzone is the same as that seen in vitiligo, the epidermis being normal except for the absence of identifiable melanocytes. Under Dosage and Administration it states that prolonged exposure to sunlight should be avoided during treatment, or that a sunscreen should be used. Under Carcinogenesis, mutagenesis, impairment of fertility it states that no long term studies have been performed to evaluate carcinogenic potential.
What it does not support
The archived label does not establish current commercial availability, approval of a compounded preparation, predictable uniform results, suitability, a personal plan, or current status outside the US. Its sun statements are the label instructing a patient under a prescriber; SteadySkin reports them as the label’s wording and issues none of them as advice. It sets no sun protection factor, no interval and no exposure limit, and it measures nothing about how depigmented skin behaves in sunlight beyond the sensitivity statement itself. Because it performed no long term carcinogenicity study, it establishes nothing about skin cancer risk after depigmentation in either direction. The document carries a printed revision of August 2000 and an FDA banner stating it may not be the latest approved label, so it is used only for what it plainly states and never as current guidance.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the distinction between Benoquin’s retained historical approval record and the FDA-reviewed statement that the branded product was no longer manufactured or distributed and its structured label had been delisted.
What it does not support
It does not establish present inventory, lawful access for one person, the quality of any compounded preparation, or status outside the US.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations. Classification is a clinical and longitudinal judgment. Its section on the Koebner phenomenon supports defining that phenomenon as patches developing at sites of previously unaffected skin that was specifically injured. It endorses the Vitiligo European Task Force classification of that phenomenon into history-based, clinical-observation-based and experimentally induced forms. Its section on mucosal vitiligo defines that term as the oral or genital mucosae. Where the patches are at one site alone, and especially a genital one, that section says a differential diagnosis of lichen sclerosus should be addressed by biopsy. It records that genital lichen sclerosus and vitiligo have been reported together.
What it does not support
It does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response. On the Koebner phenomenon it records a general impression that the phenomenon and disease stability are related, then states that objective data are lacking. It also says scientific evidence is lacking for attributing vitiligo to daily friction from washing, dressing, personal care, sports, occupational activity or pressure from clothing. On lichen sclerosus it cites one reference from 2000 and calls a link a possibility, not a finding. It counts nothing and gives no rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Association of DermatologistsPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
It supports that skin camouflage means highly pigmented products that differ from ordinary makeup. They are made for long-lasting cover, are often water resistant, and are usually set with a fixing powder or spray. It supports that they should not be treated as rub-proof. Some transfer onto clothing, furnishings and bed linen can happen, and standard household cleaning usually removes it. It supports removing camouflage daily with soap and water, a soap substitute, or an oil-based cleanser, and that hard scrubbing can irritate skin. It supports that a daily removal routine lets a person look at the skin for changes. It supports that vitiligo, birthmarks and healed scars are suitable for camouflage. It supports that an undiagnosed skin condition is not, and that skin must not be infected, inflamed, blistered or broken. It supports that colours come pre-mixed and can be blended to match, and that a second layer can be applied when one is not enough. It supports that trained camouflage advisers work in NHS outpatient, dermatology and plastic surgery settings, and in the private sector. It supports that some creams and powders are available on NHS prescription, that local policy can restrict or deny access, and that a prescriber needs the brand, colour code and size agreed at a camouflage consultation. It supports that camouflage changes the colour a person sees and does not change skin texture. It supports that products sold in supermarkets, chemists and department stores may help with minor discolouration and may not work as well as camouflage products.
What it does not support
It is a UK consensus leaflet. It sets no access, referral or prescribing route anywhere else. It names no product and ranks no brand. It cannot say how long cover lasts for one person, what a colour match will look like, or what anything costs. It does not tell a reader whether a patch is vitiligo. It is not guidance for what may be on skin before a prescribed light treatment.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.